DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
DURECT (DRRX) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The company's President and CEO, James E. Brown, will deliver a presentation on Tuesday, February 11, from 2:00-2:30 PM ET on Track 5.
The conference will be held in a virtual format, and interested parties can access the presentation through a webcast link provided. Additionally, DURECT's management team will be available for one-on-one meetings with investors during the conference. Investors seeking to arrange meetings are advised to contact their Oppenheimer representative to schedule appointments.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, DRRX gained 2.60%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Presentation details are as follows:
Date and time: | Tue, Feb 11 at 2:00-2:30 PM ET (Track 5) |
Webcast: |
DURECT management will participate in one-on-one investor meetings during the conference. Investors interested in a meeting at the conference should contact their Oppenheimer representative.
About DURECT Corporation
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Larsucosterol, DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Breakthrough Therapy designation; metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. In addition, POSIMIR®(bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved. For more information about DURECT, please visit www.durect.com and follow us on X (formerly Twitter) at https://x.com/DURECTCorp.
DURECT Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: the potential uses of larsucosterol to treat patients with AH and potentially other indications. Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from those projected include, among other things, the risk that future clinical trials of larsucosterol are delayed or do not confirm the results from subset analyses of the AHFIRM trial, including geographic or other segmentation, or of earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of larsucosterol in a statistically significant manner; the risk that we do not raise sufficient capital to commence or complete the Phase 3 clinical trial of larsucosterol in patients with AH or continue to fund our operations, the risk that the FDA or other government agencies may require additional clinical trials for larsucosterol before approving larsucosterol for the treatment of AH, the risk that Breakthrough Therapy designation does not expedite the process for FDA approval and that larsucosterol may never be approved; and risks related to the sufficiency of our cash resources, our anticipated capital requirements, our ability to meet the minimum bid price for continued listing on Nasdaq, and our ability to continue to operate as a going concern. Further information regarding these and other risks is included in DURECT's most recent Securities and Exchange Commission filings, including its annual report on Form 10-K for the year ended December 31, 2023 and quarterly report on Form 10-Q for the quarter ended September 30, 2024, under the heading "Risk Factors." These reports are available on our website www.durect.com under the "Investors" tab and on the SEC's website at www.sec.gov. All information provided in this press release is based on information available to DURECT as of the date hereof, and DURECT assumes no obligation to update this information as a result of future events or developments, except as required by law.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd. in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/durect-corporation-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference-302366991.html
SOURCE DURECT Corporation
FAQ
When is DURECT (DRRX) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access DURECT's (DRRX) presentation at the Oppenheimer Conference?
Will DURECT (DRRX) management be available for investor meetings at the Oppenheimer Conference?
Is the Oppenheimer Healthcare Conference 2025 where DRRX is presenting virtual or in-person?
